MIT Technology Review
MIT Technology Review’s 35 Innovators Under 35
Beam Therapeutics’ Nicole Gaudelli among MIT Technology Review’s 35 Innovators...
The human genome is made up of billions of nucleobases, or “bases,” represented by the letters A, G, T, and C. Beam’s base editing technology can precisely target and make specific edits to a single base in DNA or RNA, without cutting or disrupting the gene. Base editors have the potential to repair disease-causing point mutations, write in protective genetic variations, or modulate the expression or function of disease-causing genes. Beam is committed to developing base editors as a new class of precision genetic medicines that can treat or cure diseases affecting patients’ lives.
Starting with our founders and funders, we’re building a world-class team to develop precision genetic medicines through DNA and RNA base editing. Join us.
Beam seeks an experienced and highly motivated associate scientist to help advance our immunology platform, including allogeneic CAR-T programs. TheRead More
Beam seeks an experienced and highly motivated scientist to help advance our immunology platform, including allogeneic CAR-T programs. The idealRead More
Beam is looking for a highly motivated and creative Scientist/Sr. Scientist to advance our ophthalmology programs using next-generation gene editingRead More
26 Landsdowne Street
Cambridge, MA 02139